Literature DB >> 34846648

A novel low-density lipoprotein receptor variant in a Ukrainian patient: a case report and overview of the disease-causing low-density lipoprotein receptor variants associated to familial hypercholesterolemia.

Simona Moffa1,2, Maria Elisabetta Onori3, Elisa De Paolis3, Claudio Ricciardi Tenore3, Alessia Perrucci3, Alfredo Pontecorvi1,2, Andrea Giaccari1,2, Andrea Urbani3,2, Angelo Minucci4.   

Abstract

BACKGROUND: Familial hypercholesterolemia (FH) is characterized by high low-density lipoprotein-cholesterol levels and it is primarily caused by pathogenic/likely pathogenic variants (P/LPVs) in LDLR, APOB or PCSK9 genes. Next generation sequencing (NGS) technology allows the evaluation of more genes simultaneously, rising the diagnostic throughput of genomics laboratories.
MATERIALS AND METHODS: We report a Ukrainian 37-year-old woman hypercholesterolemic since 2010. Despite a suggestive family history, FH was suspected only when the patient referred to the Endocrine and Metabolic Diseases Center of the Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome. After specialist advice, genetic testing was offered to the patient at our Molecular and Genomic Diagnostics Unit.
RESULTS: A targeted NGS-based pipeline highlighted a novel out-of-frame deletion in the LDLR gene. This variant has a clear deleterious effect on the LDLR protein and it can be classified as PV.
CONCLUSIONS: The ideal model of care for FH is an evidence-based system aimed to provide the highest-quality health services to all FH patients. In fact, this study reports that the integrated care pathway adopted in our hospital for FH patients led successfully to the discovery of a novel LDLR PV in an Ukrainian patient. The finding of this LDLR variant allowed the clinical FH diagnosis in this patient and in her family, expanding the knowledge of FH-related genetic variants in the Ukrainian population.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  FH-Devyser Kit; Familial hypercholesterolemia; LDL-cholesterol; Next generation sequencing; Novel LDLR variant; Ukrainian population

Mesh:

Substances:

Year:  2021        PMID: 34846648     DOI: 10.1007/s11033-021-07015-3

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  15 in total

Review 1.  Diagnostic scoring for familial hypercholesterolaemia in practice.

Authors:  Kate Haralambos; Pauline Ashfield-Watt; Ian F W McDowell
Journal:  Curr Opin Lipidol       Date:  2016-08       Impact factor: 4.776

2.  A rapid screening of a recurrent CYP24A1 pathogenic variant opens the way to molecular testing for Idiopathic Infantile Hypercalcemia (IIH).

Authors:  Elisa De Paolis; Angelo Minucci; Maria De Bonis; Giovanni Luca Scaglione; Jacopo Gervasoni; Aniello Primiano; Pietro Manuel Ferraro; Daniele Cappellani; Claudio Marcocci; Giovanni Gambaro; Ettore Capoluongo
Journal:  Clin Chim Acta       Date:  2018-03-21       Impact factor: 3.786

3.  Identification of two novel LDLR variants by Next Generation Sequencing.

Authors:  Simona Moffa; Giorgia Mazzuccato; Maria De Bonis; Elisa De Paolis; Maria Elisabetta Onori; Alfredo Pontecorvi; Andrea Urbani; Andrea Giaccari; Ettore Capoluongo; Angelo Minucci
Journal:  Ann Ist Super Sanita       Date:  2020 Jan-Mar       Impact factor: 1.663

4.  Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics.

Authors:  R R Williams; S C Hunt; M C Schumacher; R A Hegele; M F Leppert; E H Ludwig; P N Hopkins
Journal:  Am J Cardiol       Date:  1993-07-15       Impact factor: 2.778

Review 5.  Advanced method for the identification of patients with inherited hypercholesterolemia.

Authors:  Joep C Defesche; Peter J Lansberg; Marina A W Umans-Eckenhausen; John J P Kastelein
Journal:  Semin Vasc Med       Date:  2004-02

6.  2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Authors:  François Mach; Colin Baigent; Alberico L Catapano; Konstantinos C Koskinas; Manuela Casula; Lina Badimon; M John Chapman; Guy G De Backer; Victoria Delgado; Brian A Ference; Ian M Graham; Alison Halliday; Ulf Landmesser; Borislava Mihaylova; Terje R Pedersen; Gabriele Riccardi; Dimitrios J Richter; Marc S Sabatine; Marja-Riitta Taskinen; Lale Tokgozoglu; Olov Wiklund
Journal:  Eur Heart J       Date:  2020-01-01       Impact factor: 29.983

Review 7.  The genetics and screening of familial hypercholesterolaemia.

Authors:  Raymond Henderson; Maurice O'Kane; Victoria McGilligan; Steven Watterson
Journal:  J Biomed Sci       Date:  2016-04-16       Impact factor: 8.410

Review 8.  The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project.

Authors:  Richard Ceska; Gustavs Latkovskis; Marat V Ezhov; Tomas Freiberger; Katarina Lalic; Olena Mitchenko; Gyorgy Paragh; Zaneta Petrulioniene; Belma Pojskic; Katarina Raslova; Aleksandr B Shek; Branislav Vohnout; Tereza Altschmiedova; Veronika Todorovova
Journal:  Curr Atheroscler Rep       Date:  2019-06-22       Impact factor: 5.113

Review 9.  Management of Familial Hypercholesterolemia: Current Status and Future Perspectives.

Authors:  David T W Lui; Alan C H Lee; Kathryn C B Tan
Journal:  J Endocr Soc       Date:  2020-08-21

10.  Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia: A Global Call to Action.

Authors:  Katherine A Wilemon; Jasmine Patel; Carlos Aguilar-Salinas; Catherine D Ahmed; Mutaz Alkhnifsawi; Wael Almahmeed; Rodrigo Alonso; Khalid Al-Rasadi; Lina Badimon; Luz M Bernal; Martin P Bogsrud; Lynne T Braun; Liam Brunham; Alberico L Catapano; Kristyna Cillíková; Pablo Corral; Regina Cuevas; Joep C Defesche; Olivier S Descamps; Sarah de Ferranti; Jean-Luc Eiselé; Gerardo Elikir; Emanuela Folco; Tomas Freiberger; Francesco Fuggetta; Isabel M Gaspar; Ákos G Gesztes; Urh Grošelj; Ian Hamilton-Craig; Gabriele Hanauer-Mader; Mariko Harada-Shiba; Gloria Hastings; G Kees Hovingh; Maria C Izar; Allison Jamison; Gunnar N Karlsson; Meral Kayikçioglu; Sue Koob; Masahiro Koseki; Stacey Lane; Marcos M Lima-Martinez; Greizy López; Tania L Martinez; David Marais; Letrillart Marion; Pedro Mata; Inese Maurina; Diana Maxwell; Roopa Mehta; George A Mensah; André R Miserez; Dermot Neely; Stephen J Nicholls; Atsushi Nohara; Børge G Nordestgaard; Leiv Ose; Athanasios Pallidis; Jing Pang; Jules Payne; Amy L Peterson; Monica P Popescu; Raman Puri; Kausik K Ray; Ashraf Reda; Tiziana Sampietro; Raul D Santos; Inge Schalkers; Laura Schreier; Michael D Shapiro; Eric Sijbrands; Daniel Soffer; Claudia Stefanutti; Mario Stoll; Rody G Sy; Martha L Tamayo; Myra K Tilney; Lale Tokgözoglu; Brian Tomlinson; Antonio J Vallejo-Vaz; Alejandra Vazquez-Cárdenas; Patrícia Vieira de Luca; David S Wald; Gerald F Watts; Nanette K Wenger; Michaela Wolf; David Wood; Aram Zegerius; Thomas A Gaziano; Samuel S Gidding
Journal:  JAMA Cardiol       Date:  2020-02-01       Impact factor: 14.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.